Reduced Maternal Circulating Cell‐Free Mitochondrial DNA Is Associated With the Development of Preeclampsia

Background Circulating cell‐free mitochondrial DNA (ccf‐mtDNA) is a damage‐associated molecular pattern that reflects cell stress responses and tissue damage, but little is known about ccf‐mtDNA in preeclampsia. The main objectives of this study were to determine (1) absolute concentrations of ccf‐mtDNA in plasma and mitochondrial DNA content in peripheral blood mononuclear cells and (2) forms of ccf‐mtDNA transport in blood from women with preeclampsia and healthy controls. In addition, we sought to establish the association between aberrance in circulating DNA‐related metrics, including ccf‐mtDNA and DNA clearance mechanisms, and the clinical diagnosis of preeclampsia using bootstrapped penalized logistic regression. Methods and Results Absolute concentrations of ccf‐mtDNA were reduced in plasma from women with preeclampsia compared with healthy controls ( P ≤0.02), while mtDNA copy number in peripheral blood mononuclear cells did not differ between groups ( P >0.05). While the pattern of reduced ccf‐mtDNA in patients with preeclampsia remained, DNA isolation from plasma using membrane lysis buffer resulted in 1000‐fold higher ccf‐mtDNA concentrations in the preeclampsia group ( P =0.0014) and 430‐fold higher ccf‐mtDNA concentrations in the control group ( P <0.0001). Plasma from women with preeclampsia did not induce greater Toll‐like receptor‐9–induced nuclear factor kappa‐light‐chain enhancer of activated B cells‐dependent responses in human embryonic kidney 293 cells overexpressing the human TLR‐9 gene ( P >0.05). Penalized regression analysis showed that women with preeclampsia were more likely to have lower concentrations of ccf‐mtDNA as well as higher concentrations of nuclear DNA and DNase I compared with their matched controls. Conclusions Women with preeclampsia have aberrant circulating DNA dynamics, including reduced ccf‐mtDNA concentrations and DNA clearance mechanisms, compared with gestational age–matched healthy pregnant women.

Improvements and limits of anti SARS-CoV-2 antibodies assays by WHO (NIBSC 20/136) standardization

Objectives A few CLIA automated immunoassays for the recognition of anti S1-RBD SARS-CoV-2 antibodies have recently been placed on the market. Preliminary data demonstrate a high correlation between methods but wide differences in absolute concentrations. A new WHO international standard for anti-SARS-CoV-2 immunoglobulin, NIBSC code 20/136, has been recently introduced to reduce the differences. The aim of this study is thus to verify the harmonization made by NIBSC 20/136 on Ab anti S1-RBD measurement on real samples. Methods The following assays were studied: LIAISON® SARS-CoV-2 TrimericS IgG (DiaSorin); Elecsys® anti-SARS-CoV-2 S (ROCHE); Atellica IM SARS-CoV-2 IgG (sCOVG) (Siemens); MAGLUMI® SARS-CoV-2 S-RBD IgG (Snibe), measuring 210 samples from 70 health workers with no previous SARS-CoV2 infection, during their Pfizer-BioNTech’s BNT162b2 vaccination period. Results The recalculation of concentrations based on the NIBSC 20/136 standardization improve the analytical and diagnostic comparability but do not cancel this variability between methods: recalibrated results remain different across methods, both in terms of tendency and single data. Conclusions The recalculation of concentrations based on the NIBSC 20/136 standardization improves the analytical and diagnostic comparability but does not cancel the differences between methods: recalibrated results remain different across methods, both in terms of tendency and single data.

Targeted proteomics analysis of plasma proteins using recombinant protein standards for addition only workflows

Targeted proteomics is an attractive approach for the analysis of blood proteins. Here, we describe a novel analytical platform based on isotope-labeled recombinant protein standards stored in a chaotropic agent and subsequently dried down to allow storage at ambient temperature. This enables a straightforward protocol suitable for robotic workstations. Plasma samples to be analyzed are simply added to the dried pellet followed by enzymatic treatment and mass spectrometry analysis. Here, we show that this approach can be used to precisely (coefficient of variation <10%) determine the absolute concentrations in human plasma of hundred clinically relevant protein targets, spanning four orders of magnitude, using simultaneous analysis of 292 peptides. The use of this next-generation analytical platform for high-throughput clinical proteome profiling is discussed.

Effect of Osmotic Pressure on Whey Protein Concentration in Forward Osmosis

Forward osmosis (FO) is an emerging process to dewater whey streams energy efficiently. The driving force for the process is the concentration gradient between the feed (FS) and the concentrated draw (DS) solution. Here we investigate not only the effect of the DS concentration on the performance, but also that of the FS is varied to maintain equal driving force at different absolute concentrations. Experiments with clean water as feed reveal a flux increase at higher osmotic pressure. When high product purities and thus low reverse salt fluxes are required, operation at lower DS concentrations is preferred. Whey as FS induces severe initial flux decline due to instantaneous protein fouling of the membrane. This is mostly due to reversible fouling, and to a smaller extent to irreversible fouling. Concentration factors in the range of 1.2–1.3 are obtained. When 0.5 M NaCl is added to whey as FS, clearly lower fluxes are obtained due to more severe concentration polarization. Multiple runs over longer times show though that irreversible fouling is fully suppressed due to salting in/out effects and flux decline is the result of reversible fouling only.

Development and analytical validation of a novel bioavailable 25-hydroxyvitamin D assay

Background Bioavailable 25-hydroxyvitamin D (25OHD) may be a better indicator of vitamin D sufficiency than total 25OHD. This report describes a novel assay for measuring serum bioavailable 25OHD. Methods We developed an assay for 25OHD % bioavailability based on competitive binding of 25OHD tracer between vitamin D-binding protein (DBP)-coated affinity chromatography beads and serum DBP. Bioavailable 25OHD, total 25OHD, albumin, and DBP protein concentrations were measured in 89 samples from hospitalized patients and 42 healthy controls to determine how the DBP binding assay responds to differences in concentrations of DBP and compares to calculated bioavailable 25OHD values. Results DBP binding assay showed a linear relationship between DBP-bound 25OHD tracer recovered from bead supernatant and DBP calibrator concentrations (y = 0.0017x +0.731, R2 = 0.9961, p<0.001). Inversion of this relationship allowed interpolation of DBP binding equivalents based upon 25OHD tracer recovered. The relationship between DBP binding equivalents and % bioavailability fits a non-linear curve, allowing calculation of % bioavailable 25OHD from DBP binding equivalents (y = 10.625x-0.817, R2 = 0.9961, p<0.001). In hospitalized patient samples, there were linear relationships between DBP protein concentrations and DBP binding equivalents (y = 0.7905x + 59.82, R2 = 0.8597, p<0.001), between measured vs. calculated % bioavailability (y = 0.9528 + 0.0357, R2 = 0.7200, p<0.001), and between absolute concentrations of measured vs. calculated bioavailable 25OHD (y = 1.2403 + 0.1221, R2 = 0.8913, p<0.001). Conclusions The DBP-binding assay for bioavailable 25OHD shows expected changes in 25OHD % bioavailability in response to changes in DBP concentrations and concordance with calculated bioavailable 25OHD concentrations.

Presence and Levels of Galactosyllactoses and Other Oligosaccharides in Human Milk and Their Variation during Lactation and According to Maternal Phenotype

Among the human milk oligosaccharides (HMOS), the galactosyllactoses (GLs) are only limitedly studied. This study aims to describe the presence and relative levels of HMOS, including GLs, in human milk (HM) according to maternal Secretor and Lewis (SeLe) phenotype and lactation stage. Relative levels of 19 HMOS were measured in 715 HM samples collected in the first 4 months postpartum from 371 donors participating in the PreventCD study. From a subset of 24 Dutch women (171 HM samples), samples were collected monthly up to 12 months postpartum and were additionally analyzed for relative and absolute levels of β6′-GL, β3′-GL and α3′-GL. Maternal SeLe phenotype or HM group was assigned based on the presence of specific fucosylated HMOS. Most HMOS, including β6′- and β3′-GL, were present in the vast majority (≥75%) of HM samples, whereas others (e.g., LNDFH II, 2′-F-LNH and α3′-GL) only occurred in a low number (<25%) of samples. Clear differences were observed between the presence and relative levels of the HMOS according to the maternal phenotype and lactation stage. Absolute concentrations of β6′-GL and β3′-GL were higher in HM group IV samples compared to samples of the other three HM groups. β3′-GL was also higher in HM group II samples compared to HM group I samples. β3′-GL and β6′-GL were stable over lactation stages. In conclusion, presence and levels of HMOS vary according to HM group and lactation stage. Not all HMOS behave similarly: some HMOS depend strongly on maternal phenotype and/or lactation stage, whereas others do not. β3′-GL and β6′-GL were present in low concentrations in over 75% of the analyzed HM samples and showed differences between HM groups, but not between the lactation stages.

Leveraging the mass balances of cellular metabolism to infer absolute concentrations from relative abundance metabolomics data

Motivation: As the large-scale study of metabolites and a direct readout of a system's metabolic state, metabolomics has significant appeal as a source of information for many metabolic modeling platforms and other metabolic analysis tools. However, metabolomics data are typically reported in terms of relative abundances, which precluding use with tools where absolute concentrations are necessary. While chemical standards can be used to determine the absolute concentrations of metabolites, they are often time-consuming to run, expensive, or unavailable for many metabolites. A computational framework that can infer absolute concentrations without the use of chemical standards would be highly beneficial to the metabolomics community. Results: We have developed and characterized MetaboPAC, a computational strategy that leverages the mass balances of a system to infer absolute concentrations in metabolomics datasets. MetaboPAC uses a kinetic equations approach and an optimization approach to predict the most likely response factors that describe the relationship between absolute concentrations and their relative abundances. We determined that MetaboPAC performed significantly better than the other approaches assessed on noiseless data when at least 60% of kinetic equations are known a priori. Under the most realistic conditions (low sampling frequency, high noise data), MetaboPAC significantly outperformed other methods in the majority of cases when 100% of the kinetic equations were known. For metabolomics datasets extracted from systems that are well-studied and have partially known kinetic structures, MetaboPAC can provide valuable insight about their absolute concentration profiles.

Personalized metabolic profile by synergic use of NMR and HRMS

A new strategy that takes advantage of the synergism between NMR and LC-HRMS (SYNHMET), and that allows to obtain a unique list of the absolute concentrations of 164 metabolites in urine, is presented. Metabolite identification and quantification by this method in one of the most difficult biofluids to characterize, due to complexity and variability, is more accurate than what can be obtained using the two techniques separately. This result is achieved without the need for chemical reactions to cross-check the data between the two types of spectra, nor the use of analytical standards and calibration curves. The fact that the absolute rather than relative concentration is obtained allows the final dataset to be used to determine a patient's personalized profile. The number of quantifiable metabolites by the application of this method can be expanded in the future with further analysis. We will illustrate the use of SYNHMET in the study of urine samples from healthy subjects, patients with chronic cystitis and bladder cancer.

An electronic circular dichroism spectroscopy method for the quantification of L- and D-amino acids in enantiomeric mixtures

Rapid quantitative analysis of single chiral amino acid (aa) was achieved using circular dichroism (CD) with data analysis by standard calibration curve. The absolute concentrations of D- and L-aas in enantiomeric mixtures were determined by CD and achiral liquid chromatography (LC) method. It is worth noting that CD and LC were used independently, not online LC/CD in this study. The errors of the experimental results were less than 10%. The method is also applicable to the quantification of non-aa chiral molecules, such as chiral nucleoside and chiral quinine. With this study, we provide a new method for the chiral quantitative analysis of enantiomeric aas mixtures.

Investigation on the biodegradation levels of super heavy oils by parameter-striping method and refined Manco scale: a case study from the Chepaizi Uplift of Junggar Basin

The Carboniferous volcanic reservoir in the Chepaizi Uplift became an exploration hot target in recent years for its substantial amount of oils discovered. However, most of the Carboniferous heavy oils were biodegraded to PM7 or higher with orders of magnitude variation in oil viscosities. Two oil groups (I and II) exactly corresponding to the western and eastern Chepaizi Uplift were distinguished according to their source diagnose. Furthermore, three oil families (II1, II2 and II3), with the biodegradation level of PM7, PM8–8+, PM9+, respectively, were classified based on molecular compositions and parameter-stripping method of strongly bioresistant parameters. Allowing for this extremely high biodegradation case, more biodegradation refractory compound class were added to establish a refined Manco scale to quantitatively evaluate the biodegradation extent. Refined Manco number (RMN2) positively correlated with the oil density, NSO contents, and absolute concentrations of diasteranes and gammacerane, negatively correlated with the absolute concentrations of diahopane, summed tricyclic terpanes and pentacyclic terpanes. This refined scale showed higher resolution than the PM one to differentiate the biodegradation extent of Carboniferous heavy oils from the Chepaizi Uplift, especially those with same PM values but different oil viscosities.